Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain

PURPOSE: Tisagenlecleucel, a chimeric antigen receptor T-cell (CAR-T) therapy, is a promising alternative for the management of children and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia (r/r ALL). The aim of this study was to determine whether treatment with tisagenl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribera Santasusana, Josep Maria, de Andrés Saldaña, Alejandra, García-Muñoz, Nuria, Gostkorzewicz, Joana, Martínez Llinàs, Diana, Díaz de Heredia, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237114/
https://www.ncbi.nlm.nih.gov/pubmed/32523362
http://dx.doi.org/10.2147/CEOR.S241880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237114/
https://www.ncbi.nlm.nih.gov/pubmed/32523362
http://dx.doi.org/10.2147/CEOR.S241880

Ejemplares similares